TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02311985

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Coagulogram-based protocol
Description: The interventions for this protocol include transfusion of fresh frozen plasma, platelets (random or aphaeresis) and/or cryoprecipitate, based on international normalised ratio (INR), partial thromboplastin time (PTT), platelet count and/or fibrinogen. If INR \>1.5 or PTT \>50 sec., fresh frozen plasma is administered (dose: 10 mL/Kg); and/or platelets \<50,000/microliter, random or aphaeresis platelets are administered (01 unit/Kg or 01 aphaeresis); and/or fibrinogen \<150 mg/dL, cryoprecipitate is administered (dose: 01 unit/Kg).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Thromboelastometry-based protocol
Description: The interventions for this protocol include transfusion of fresh frozen plasma, platelets (random or aphaeresis) and/or cryoprecipitate, based on rotational thromboelastometry (ROTEM(R)). If CTex \<80 sec. and A10ex \>40 mm, then no blood transfusion is performed; when CTex \>80s, then fresh frozen plasma is administered (dose: 10 mL/Kg); and/or A10ex \<40 mm or A10fib \>10 mm, random or aphaeresis platelets are administered (01 unit/Kg or 01 aphaeresis); and/or A10ex \<40 mm or A10fib \<10 mm, cryoprecipitate is administered (dose: 01 unit/Kg).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Restrictive strategy
Description: The interventions for this protocol include transfusion of fresh frozen plasma and/or platelets (random or aphaeresis), based on INR and platelet count. If INR \>5, fresh frozen plasma is administered (dose: 10 mL/Kg); and/or platelets \<25,000/microliter, random or aphaeresis platelets are administered (01 unit/Kg or 01 aphaeresis).
Study: NCT04461314

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: peer-led counselling
Description: About 50 university students will be trained as peer counsellors through a structured training programme. A pre and post and 6-month self-administered questionnaire will be conducted before, immediately and 6-month after the training programme to examine their changes of knowledge and attitudes. A satisfaction survey will also be conducted to measure participants' perception of the quality of the training programme.~Drug-abusing youth and young adults will receive telephone-based, Peer-led Brief Motivational Interviewing (BMI) counselling to rehabilitate from drug abuse. The peer counsellors will give referral advice if the youth and young adult needs appropriate treatment and rehabilitation services.~The drug abusers will be counselled and invited to complete the follow-up questionnaires at 1 week, 1 month, 3 months, 6 months, 9 months and 1 year. Self-reported quitters at 6-month and 1-year follow-ups will be invited to have a urine test to validate the drug abuse abstinence.
Study: NCT02410317

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Study: NCT02036606

Intervention type: BEHAVIORAL
Intervention: questionary

Intervention type: BEHAVIORAL
Intervention: questionary
Study: NCT04695314

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Massage
Description: Foot reflexology board (JAPAN TSUBO HH-700) with massage focused at the base of the second and third toes

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Experimental insert
Description: Raised shoe insert, insert used for massage

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Experimental insert
Description: Raised shoe insert, insert used for massage

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sham insert
Description: Flat shoe insert, insert used for massage

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sham insert
Description: Flat shoe insert, insert used for massage
Study: NCT01630837

Intervention type: OTHER
Group type: OTHER
Intervention: frequency of oral hygiene
Description: the frequency of oral hygiene was 12 to 12 hours, 24 to 24 hours, 48 to 48 hours and 72 to 72 hours.

Intervention type: OTHER
Group type: OTHER
Intervention: frequency of oral hygiene
Description: the frequency of oral hygiene was 12 to 12 hours, 24 to 24 hours, 48 to 48 hours and 72 to 72 hours.
Study: NCT02848989

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Qigong Mind-Body Exercise
Description: An exercise program that involves gentle movements combined with breathing/relaxation techniques
Study: NCT02433067

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical activity intervention
Description: Patients in arm A (interventional) will carry out a physical activity intervention during 3 months. Patients should perform an interval training program on cycle-ergometer during 3 sessions per week.
Study: NCT00700518

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo cream
Description: placebo cream applied to 2 adjacent fingers of non-dominant hand one time

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glyceryl Trinitrate
Description: 0.6mg of Glyceryl Trinitrate applied to 2 adjacent fingers on non-dominant hand one time

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glyceryl Trinitrate
Description: 1.2mg Glyceryl Trinitrate topically to 2 adjacent fingers of non-dominant hand one time

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glyceryl Trinitrate
Description: 1.8mg Glyceryl Trinitrate topically to 2 adjacent fingers of non-dominant hand one time

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glyceryl Trinitrate
Description: 2.4 mg Glyceryl Trinitrate topically to 2 adjacent fingers of non-dominant hand one time
Study: NCT03421600

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: blue laser imaging
Description: blue laser imaging

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: White light imaging
Description: White light imaging
Study: NCT04832815

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Equine Therapy
Description: Aim 1: Six session equine interventions. Intervention will be provided one day per week for four weeks. During the first two weeks, each intervention day with consist of two sessions with a lunch break in between. Weeks four and five consist of one trail riding session per intervention day followed by lunch. Each session will be approximately 1.5 hours in length. Sessions 1-4 will occur at the USU Equine Education Center, and session 5-6 will occur on local trails. Optional transportation for participants will be provided from the VA to the intervention site.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Therapeutic Horsemanship Program
Description: Aim 2: Therapeutic Horsemanship program utilizes the USU Pathways to Horsemanship model and covers levels of equestrian training from basic groundwork to more advanced riding techniques. Training occurs in a three or six-session format with once weekly sessions over three or six weeks. Mindfulness and mindful self-compassion training may be included.
Study: NCT04602039

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Bovine Colostrum
Description: Bovine colostrum (Neovite)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Bovine Colostrum
Description: Bovine colostrum (Neovite)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Bovine Colostrum
Description: Bovine colostrum (Neovite)
Study: NCT02604342

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alectinib
Description: Participants will receive oral alectinib at a dose of 600 mg twice daily, taken with food until disease progression, unacceptable toxicity, withdrawal of consent or death.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: Participants will receive docetaxel at a dose of 75 mg/m\^2 of body surface area intravenously every 3 weeks, until disease progression, unacceptable toxicity, withdrawal of consent or death.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pemetrexed
Description: Participants will receive pemetrexed at a dose of 500 mg/m\^2 of body surface area intravenously every 3 weeks, until disease progression, unacceptable toxicity, withdrawal of consent or death.
Study: NCT04512898

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triple therapy for H.pylori
Description: Triple therapy of proton pump inhibitors, clarithromycin and metronidazole.
Study: NCT01702519

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: nicotine
Description: nicotine transdermal patch

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: nicotine
Description: nicotine transdermal patch
Study: NCT03738397

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Upadacitinib
Description: Extended release tablet

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dupilumab
Description: Dupilumab is administered as a subcutaneous (SC) injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to dupilumab
Description: Placebo administered as a subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to upadacitinib
Description: Tablet
Study: NCT04248036

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Circle of Security - Parenting, COS-P
Description: Circle of Security - Parenting is a manual-based, psychoeducational intervention program in group that includes 8 group sessions of 90 minutes each.
Study: NCT01891656

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing
Description: MI is a client centered, directive style of interacting with a person to help explore and resolve ambivalence about change (Miller \& Rollnick, 2002). MI borrows from Client-Centered Counseling in its emphasis on empathy, optimism, and respect for client choice (Rogers, 1961). MI also draws from Self-Perception Theory, which says that a person becomes more or less committed to an action based on the verbal stance he or she takes (Bem, 1972). The effects of MI tend to be in the small-to-medium range when compared to no treatment, and nonsignificant when compared to more extensive treatment.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Computer
Description: The growing use of technology has led to the development of automated interventions for behavior change, including some that target drug and alcohol use (Elliott, et al, 2008; Lustria, et al, 2009; Revere \& Dunbar, 2001; Walters, et al, 2006) and treatment interest (Lieberman \& Massey, 2008). As discussed by Hester \& Miller (2006), automated interventions have several potential advantages over face-to-face interventions: (I) They require little or no staff contact, which may increase cost-effectiveness; (2) they can allow for automatic data collection and follow-up; and (3) they can be disseminated with little loss of fidelity.
Study: NCT02780739

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Training - 48 sessions
Description: Mind Frontiers cognitive training software (Aptima Inc.) is a Wild West-themed Android application played on Nexus 10 tablets. This intervention includes 20 70-min sessions (23.33 hrs) completed over 12 weeks: 1/wk weeks 5-8, 2/wk weeks 9-16. The 6 mini-games, played in random order for 10 min each session, are Ante Up (Tower of London, executive functioning); Irrigator (visuospatial reasoning); Pen 'Em Up (dual task switching, executive function); Supply Run (Keep Track, working memory updating); Riding Shotgun (visuospatial working memory); and Sentry Duty (dual n-back, working memory). There is also a meta-game in which players build a town using resources earned from the mini-games, played for 5 min each session.
Study: NCT02433067

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control Group
Description: standard oncologic care
Study: NCT03101852

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Plumpy Nut

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Plumpy Sup
Study: NCT00671827

Intervention type: BEHAVIORAL
Intervention: Questionnaire
Description: Questionnaires each taking less than 10 minutes to complete.
Study: NCT01404208

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: D-Cycloserine
Description: 25mg dose for children weighing between 22.5kg and 45kg (dose = approx. .7mg/kg) 50mg dose for children weighing greater than 46kg (dose = approx. .7mg/kg) Dose given 7 times, every seven days, except for the third dose, which will be given three days after the second dose. All doses given 1 hour prior to therapy session.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sugar pill
Study: NCT00739505

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Asfotase Alfa
Description: The initial IV dose to be administered to patients was set at one-tenth the no adverse effect level (NOAEL) as determined by one month toxicology studies in animals in which Asfotase Alfa was administered as a single weekly IV dose. The SC doses to be administered are lower than the IV doses and are thought to be near or at the anticipated daily efficacious dose. Dosing will be as follows:~Cohort 1: In Week 1, patients will receive an IV infusion of Asfotase Alfa at a dose of 3 mg/kg. In Weeks 2, 3 and 4, patients will receive weekly SC injections of Asfotase Alfa at a dose of 1 mg/kg SC.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Asfotase Alfa
Description: Cohort 2: In Week 1, patients will receive an IV infusion of Asfotase Alfa at a dose of 7 mg/kg. In Weeks 2, 3 and 4, patients will receive weekly SC injections of Asfotase Alfa at a dose of 1.5 mg/kg SC.
Study: NCT03589118

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Qi Gong sessions
Description: 13 sessions of Qi Gong in a 9 weeks period
Study: NCT00778102

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-FU
Description: Bolus 400mg/m2, day 1 every 2 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-FU
Description: 3200mg/m2 46-hour continuous iv infusion, day 1 every 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-FU
Description: 2400mg/m2 46-hour continuous iv infusion, day 1 every 2 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Irinotecan
Description: 165mg/m2 1-hour iv infusion, day 1 every 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: 400mg/m2 2-hour iv infusion, day 1 every 2 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Leucovorin
Description: 200mg/m2 2-hour iv infusion, day 1 every 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: 85mg/m2 2-hour iv infusion, day 1 every 2 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin
Description: 85mg/m2 2-hour iv infusion, day 1 every 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab [Avastin]
Description: 5mg/kg iv day 1 every 2 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bevacizumab [Avastin]
Description: 5mg/kg iv day 1 every 2 weeks
Study: NCT01758198

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Abatacept

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo matching with Abatacept

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Methotrexate
Study: NCT00800605

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vero cell-derived, trivalent, seasonal influenza vaccine
Description: Single intramuscular injection

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo: Phosphate-buffered saline
Description: Single intramuscular injection
Study: NCT03284372

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Text Message Only
Description: The intervention group (n=25, randomly selected from the base cohort) will receive informational and socially supportive text messages during a 10-week intervention. Investigators will deploy the intervention using the Way to Health platform, which automates outgoing messages and feedback. Many of the messages will be sent to all Intervention 1 participants, to assure consistency of the intervention. A subset will be tailored to address participants' specific allergies. At 10 unannounced check-ins, we will send text messages asking participants in the intervention and control groups if they are carrying their epinephrine.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Text message + Incentive 1
Description: Among base cohort members not exposed to the text message only intervention (#1), we will randomly select a new intervention group (n=50) to receive text message reminders plus Incentive 1. At each of 10 unannounced check-ins, if unsuccessful in documenting epinephrine-carrying, participants will lose part of their incentive. The remainder of the Cohort (control) will receive text reminders.
Study: NCT00703287

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physiotherapy
Description: Specialized physiotherapy programme developed by Jean-Pierre Bleton

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Physiotherapy
Description: Generic physiotherapy
Study: NCT01451632

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MM-121
Description: escalating doses MM-121 IV QW

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MM-121
Description: escalating doses MM-121 IV QW

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: 180 mg/m2 IV Q2W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: escalating doses cetuximab IV QW

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: escalating doses cetuximab IV QW
Study: NCT04240457

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Epithelial-on Corneal Crosslinking with the PXL 330 Platinum system.
Description: PXL-330 Platinum device for crosslinking with Peschke riboflavin solution. Riboflavin will be used to load the cornea, followed by UV-A crosslinking of the cornea.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Epithelial-on Corneal Crosslinking with the PXL 330 Platinum system.
Description: PXL-330 Platinum device for crosslinking with Peschke riboflavin solution. Riboflavin will be used to load the cornea, followed by UV-A crosslinking of the cornea.
Study: NCT02672007

Intervention type: DEVICE
Group type: OTHER
Intervention: SensiumVitals
Description: The patients will have their respiratory rates, heart rates and temperature (axilla) measured continuously by the SensiumVitals patch.
Study: NCT02035774

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: LSIB + SSNB
Description: Patients will receive LSIB (31 ml ropivacaine 7.5 mg/ml)+ SSNB (4 ml Ropivacaine 5 mg/ml) or LSIB (31 ml ropivacaine 7.5 mg/ml)+ SSNB (4 ml placebo, saline)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: LSIB + SSNB
Description: Patients will receive LSIB (31 ml ropivacaine 7.5 mg/ml)+ SSNB (4 ml Ropivacaine 5 mg/ml) or LSIB (31 ml ropivacaine 7.5 mg/ml)+ SSNB (4 ml placebo, saline)
Study: NCT01549262

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Observe embryo development with Unisense FertiliTech A/S (EC Certificte DGM - 673)
Description: Observation of exact timing of embryo cleavages together with other morphology dynamics parameters.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Observe embryo development
Description: Observe embryo development in the traditional manner
Study: NCT01455181

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NPSP558
Description: 50, 75, 100 μg
Study: NCT04747444

Intervention type: OTHER
Group type: OTHER
Intervention: Anti-Gravity Treadmill
Description: Treadmill in which the body weight percent placed on the lower extremities can be controlled

Intervention type: OTHER
Group type: OTHER
Intervention: Anti-Gravity Treadmill
Description: Treadmill in which the body weight percent placed on the lower extremities can be controlled
Study: NCT01378975

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vemurafenib
Description: 960 mg oral doses twice daily until disease progression, unacceptable toxicity or consent withdrawal.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vemurafenib
Description: 960 mg oral doses twice daily until disease progression, unacceptable toxicity or consent withdrawal.
Study: NCT04472026

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Counseling using the electronic conversation aid
Description: This conversation aid will help you and your doctor discuss ways to care for your thyroid nodule. We will evaluate the acceptability of the conversation aid and barriers to implementation in clinical practice. Post visit semi structured interviews and recordings of the clinical visits will be qualitatively analyzed. We hypothesize that the conversation aid will be accepted and facilitate the decision making process.
Study: NCT01465633

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: levothyroxine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: levothyroxine
Study: NCT01420679

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pralatrexate Injection
Description: Intravenous (IV) push administration over 30 seconds to 5 minutes via a patent IV line containing normal saline (0.9% sodium chloride).~Initial dose: 30 mg/m2~Administered weekly for 3 weeks of a 4-week cycle until criteria for discontinuation per the protocol are met.
Study: NCT03077659

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NanoPac®
Description: Subjects with prostate cancer scheduled for prostatectomy will have NanoPac® injected intratumorally under image guidance directly into the lobe of the prostate with the dominant lesion 4 weeks prior to prostatectomy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NanoPac®
Description: Subjects with prostate cancer scheduled for prostatectomy will have NanoPac® injected intratumorally under image guidance directly into the lobe of the prostate with the dominant lesion 4 weeks prior to prostatectomy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NanoPac®
Description: Subjects with prostate cancer scheduled for prostatectomy will have NanoPac® injected intratumorally under image guidance directly into the lobe of the prostate with the dominant lesion 4 weeks prior to prostatectomy.
Study: NCT00787917

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omalizumab
Description: Omalizumab subcutaneous injections of 600 mg daily.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo subcutaneous injections blinded to match experimental arm dosing regimen.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: Itraconazole twice daily with a maximum daily dose of 400 mg.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Itraconazole
Description: Itraconazole twice daily with a maximum daily dose of 400 mg.